Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning
Part of paid clinical trials in Manhasset, New York.
- Sponsor
- Fred Hutchinson Cancer Center
- Study ID
- NCT04515810
- Status
- Recruiting
Conditions
- Locally Advanced Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm
- Recurrent Hematologic Malignancy
- Refractory Hematologic Malignancy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Internet-Based Intervention — OTHERUse smartphone application
- Best Practice — OTHEREngage in standard care
- Telephone-Based Intervention — OTHERReceive check-in call
- Questionnaire Administration — OTHERAncillary studies
- Post-intervention qualitative feedback interview — OTHERPost-intervention qualitative feedback interview (with a subset of patients and support persons)
Study Details
This clinical trial tests a new mobile health application (app) called Planning Advance Care Together (PACT) to help people with cancer talk about and plan for advance care planning (the care they would want if they were unable to communicate) with their loved ones and doctors. The development of the PACT mobile app may help future patients incorporate their social network (typically, but not exclusively, family) into the advance care planning process.
Key Dates
- First listed
- Aug 17, 2020
- Start date
- Feb 18, 2025
- Status verified
- Jun 2026
- Primary completion
- Aug 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 400 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Experimental: Arm I (PACT)Participants use PACT mHealth app for up to 4 weeks and receive one check-in call on study.
- Active Comparator: Arm II (standard care)Participants engage in standard care with no modifications for up to 4 weeks.
Primary Outcome Measure
Feasibility: Accrual rates [Patients] [ Time Frame: At 3 months post-randomization ]
Central Contacts
- Claudia De Los Santos, B.S.206-667-1565
- Megan Shen, PhD206-667-4172
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Northwell Health | Manhasset | New York | 11030 | Daniel McFarland (PRINCIPAL_INVESTIGATOR) |
| Mount Sinai Hospital | New York | New York | 10029 | - |
| NYP/Weill Cornell Medical Center | New York | New York | 10065 | Holly Prigerson (PRINCIPAL_INVESTIGATOR) |
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | Megan J Shen, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Manhasset, NY
Related Studies
- Collection and Storage of Tissue and Blood Samples From Patients With CancerRecruiting · National Cancer Institute LAO · Fort Smith, Arkansas
- CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)PHASE1/PHASE2 · Recruiting · Curis, Inc. · Phoenix, Arizona
- PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric CancerPHASE1 · Recruiting · City of Hope Medical Center · Duarte, California
- Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerPHASE1 · Recruiting · Fred Hutchinson Cancer Center · Seattle, Washington